Considerations for Management of Longitudinal Melanonychia During the COVID-19 Pandemic: An International Perspective
Lipner, Shari R. ; Iorizzo, Matilde ; Jellinek, Nathaniel ; Piraccini, Bianca Maria ; Scher, Richard K.
Citations
Student Authors
Faculty Advisor
Academic Program
UMass Chan Affiliations
Document Type
Publication Date
Keywords
SARS-CoV-2
coronavirus
dermoscopy
en bloc excision
hemostasis
longitudinal melanonychia
melanocytic activation
nail biopsy
nail matrix nevus
nail unit melanoma
onychoscopy
pandemic
subungual melanoma
telemedicine
Dermatology
Health Services Administration
Infectious Disease
Skin and Connective Tissue Diseases
Telemedicine
Virus Diseases
Subject Area
Collections
Embargo Expiration Date
Link to Full Text
Abstract
To the editor: 34 Longitudinal melanonychia (LM) is the presenting sign of nail unit melanoma (NUM) in 2/3 35 of cases and is therefore among the most important conditions managed by dermatologists. In 36 normal times, referral for LM would prompt an expedited appointment for clinical 37 examination and dermoscopy.1 However, due to SARS-CoV-2, dermatologists have been 38 asked to reconsider “urgent/emergency” conditions. The COVID-19 pandemic has propelled 39 physicians to unexpectedly adopt telemedicine without adequate guidance for managing LM 40 patients.
Source
Lipner SR, Iorizzo M, Jellinek N, Piraccini BM, Scher RK. Considerations for Management of Longitudinal Melanonychia During the COVID-19 Pandemic: An International Perspective. J Am Acad Dermatol. 2020 May 13. doi: 10.1016/j.jaad.2020.05.028. Epub ahead of print. PMID: 32405124; PMCID: PMC7217794. Link to article on publisher's site